Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa in Overweight and Obesity (Phase II PK/PD)
CTR20240801Phase 2Completed
- Sponsor
- Yinno Pharma
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of efsubaglutide alfa in obesity, Overweight, sponsored by Yinno Pharma. Started Mar 2024; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20240801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240801.